Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

Trial end-of-treatment readouts are mixed: ENRICH reported higher HBsAg loss rates, aligning with ENSURE Cohort 4 and supporting BRII-179 as an immune-priming component for functional cure strategies. However, ENHANCE end-of-treatment data did not show improved HBsAg loss rates versus the comparator, keeping efficacy evidence inconclusive.

Analysis

Trial end-of-treatment readouts are mixed: ENRICH reported higher HBsAg loss rates, aligning with ENSURE Cohort 4 and supporting BRII-179 as an immune-priming component for functional cure strategies. However, ENHANCE end-of-treatment data did not show improved HBsAg loss rates versus the comparator, keeping efficacy evidence inconclusive.